New perspectives in the management of small cell lung cancer

Table 3 Combined first-line immunotherapy options for extensive-stage small cell lung cancer

Study	n	Design	Treatment	RR	PFS	OS
NCT01450761	1132	Phase III; Randomized, double-blind; Drug: Ipilimumab	Arm A: PE × 4C + ipilimumab × 4C; Control: PE × 4C + placebo × 4C	PR 62% vs 62%; SD 26% vs 27%; PD 6% vs 9%	4.6 vs 4.4 mo; HR = 0.85, P = 0.0161	11.0 vs 10.9 mo; HR = 0.94, P = 0.3775
Impower 133	403	Phase III. Randomized, double-blind; Drug: Atezolizumab	Arm A: PE + atezolizumab × 4C/atezolizumab; Control: PE + placebo × 4C/placebo	60% vs 64%	5.2 vs 4.3 mo; HR = 0.77, P = 0.02	12.3 vs 10.3 mo; HR = 0.70, P = 0.007
CASPIAN	805	Phase III. Randomized, open-label; Drug: Durvalumab	Arm B (n = 268): Durvalumab + PE × 4C/durvalumab; Control: PE × 4C	68% vs 58%	5.1 vs 5.4 mo; HR = 0.78, P not tested	13.0 vs 10.3 mo; HR = 0.73, P = 0.0047
CASPIAN	805	Phase III. Randomized, open-label; Drug: Durvalumab + tremelimumab	Arm A (n = 268): Durvalumab + tremelimumab + PE × 4C/durvalumab + tremelimumab. Control: PE × 4C	58% both arms	4.9 vs 5.4 mo; HR = 0.84	10.4 vs 10.5 mo; HR = 0.82, P = 0.045
KEYNOTE 604	453	Phase III; Randomized, double-blind; Drug: Pembrolizumab	Arm A: Pembrolizumab + PE; Control: PE + placebo	71% vs 62%	4.5 vs 4.3 mo; HR = 0.75, P = 0.0023	10.8 vs 9.7 mo; HR = 0.80, P = 0.0164
ECOG-ACRIN	160	Phase I. Randomized, open-label; Drug: Nivolumab	Arm A: PE + nivolumab × 4C/nivolumab; Control: PE × 4C	52.29% vs 47.71%	5.5 vs 4.6 mo; HR = 0.65, P = 0.012	11.3 vs 8.5 mo; HR = 0.67, P = 0.038

4C: 4 cycles; OS: Overall survival; PD: Progressive disease; PE: Platinum and etoposide; PFS: Progression free survival; PR: Partial response; RR: Response rate; SD: Stable disease.